Zimmer Biomet announced the departure of David Dvorak, its CEO of ten years. Dan Florin, Senior Vice President and CFO, will serve as interim CEO while the board seeks to fill the position.
Carmell Therapeutics closed a US $4MM Series B financing. Funds will support Phase III clinical development of the company’s Bone Healing Accelerant product.